Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Celgene Corporation (“Celgene”) (NASDAQ: CELG) common stock between April 27, 2017 and April 27, 2018, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as knowingly or recklessly failed to disclose that: (1) GED-0301, Celgene’s late-stage developmental treatment for Crohn's disease, had not shown meaningful or sustained efficacy through the interim endoscopy trial, and the phase III trial had a materially greater likelihood of failure than publicly disclosed; (2) despite this, company executives’ claimed, among other things, that GED-0301 continued to show transformative promise, the company's 2020 guidance would be met or exceeded, and that Celgene would be able to develop the revenue streams necessary to continue the company's growth; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On November 4, 2025, Kessler Topaz, on behalf of the Lead Plaintiffs, filed a Motion for Preliminary Approval of the Class Action Settlement, which is scheduled for a hearing on December 2, 2025. This action is ongoing.
For more information on the case and the Proposed Settlement, please visit our website at https://www.ktmc.com/featured-case/celgene-corp-inc.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.